https://orcid.org/0000-0002-8703-4611
References
- Sackett DL, Rosenberg WM, Gray JA, et al Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71–72.
- Rizkallah M, Assi A, Otayek J, et al. What's important: foundations of orthopaedics-the "multiple-of-three rule": where is the evidence? J Bone Joint Surg Am. 2018;100:1165–1166.
- Funahashi Y, Yoshino Y, Sassa N, et al. Comparison of warm and cold ischemia on renal function after partial nephrectomy. Urology. 2014;84:1408–1413.
- Parekh DJ, Weinberg JM, Ercole B, et al. Tolerance of the human kidney to isolated controlled ischemia. J Am Soc Nephrol. 2013;24:506–517.
- Mellick LB, Sinex JE, Gibson RW, et al. A systematic review of testicle survival time after a torsion event. Pediatr Emerg Care. 2019;35:821–825.
- Desgrandchamps F, De La Taille A, Doublet JD, RetenFrance Study Group. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia. BJU Int. 2006;97:727–733.
- Matsumoto K, Niwa N, Hattori S, et al. Establishment of the optimal follow-up schedule after radical prostatectomy. Urol Oncol Semin Orig Investig. 2018;36:341.e9–341-e14.
- Hori S, Tanaka N, Nakai Y, et al Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient's age and prostate volume. Res Rep Urol. 2019;11:61–68.
- Bolla M, de Reijke TM, Van Tienhoven G, et al.; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516–2527.
- Nabid A, Carrier N, Martin A-G, et al. Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol. 2018;74:432–441.